Aquestive Therapeutics Inc (NASDAQ:AQST) has earned an average rating of “Buy” from the seven research firms that are currently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. The average 12 month price objective among brokers that have covered the stock in the last year is $23.00.

Several research firms recently weighed in on AQST. HC Wainwright cut their price target on shares of GENFIT S A/ADR to $72.00 and set a “buy” rating on the stock in a report on Monday, April 22nd. Zacks Investment Research cut shares of GreenTree Hospitality Group from a “buy” rating to a “hold” rating in a report on Monday, May 20th. Finally, Wedbush set a $51.00 price target on shares of Kala Pharmaceuticals and gave the company a “buy” rating in a report on Friday, July 5th.

Shares of Aquestive Therapeutics stock traded up $0.05 on Monday, hitting $3.65. The stock had a trading volume of 180,463 shares, compared to its average volume of 141,546. The company has a debt-to-equity ratio of 4.23, a quick ratio of 1.71 and a current ratio of 1.89. Aquestive Therapeutics has a one year low of $3.53 and a one year high of $20.70. The firm has a market cap of $89.91 million and a PE ratio of -1.30. The firm has a 50-day moving average of $4.24.

Aquestive Therapeutics (NASDAQ:AQST) last issued its earnings results on Wednesday, May 8th. The company reported ($0.59) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.49) by ($0.10). The firm had revenue of $12.64 million for the quarter, compared to analysts’ expectations of $10.66 million. On average, equities analysts anticipate that Aquestive Therapeutics will post -2.56 EPS for the current fiscal year.

A number of large investors have recently added to or reduced their stakes in the stock. New York State Common Retirement Fund bought a new stake in Aquestive Therapeutics in the fourth quarter valued at $28,000. Spark Investment Management LLC bought a new stake in Aquestive Therapeutics in the first quarter valued at $80,000. Bank of New York Mellon Corp bought a new stake in Aquestive Therapeutics in the fourth quarter valued at $108,000. Geode Capital Management LLC boosted its holdings in Aquestive Therapeutics by 77.6% in the fourth quarter. Geode Capital Management LLC now owns 44,208 shares of the company’s stock valued at $278,000 after acquiring an additional 19,310 shares in the last quarter. Finally, Millennium Management LLC bought a new stake in Aquestive Therapeutics in the fourth quarter valued at $145,000. Institutional investors and hedge funds own 66.21% of the company’s stock.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc, a specialty pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; and Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery in the United States and internationally.

Recommended Story: What is the return on assets formula?

Analyst Recommendations for Aquestive Therapeutics (NASDAQ:AQST)

Receive News & Ratings for Aquestive Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquestive Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.